Focused On-demand Library for Natriuretic peptides A

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P01160

UPID:

ANF_HUMAN

Alternative names:

Atrial natriuretic factor prohormone; Atrial natriuretic peptide prohormone; Atriopeptigen; Cardiodilatin; preproCDD-ANF

Alternative UPACC:

P01160; Q13766; Q5JZE1

Background:

Natriuretic peptides A, known by various names such as Atrial natriuretic factor prohormone and Cardiodilatin, plays a pivotal role in cardio-renal homeostasis. It regulates blood pressure, fluid-electrolyte balance, and inhibits aldosterone synthesis through its actions on vasodilation, natriuresis, and diuresis. Its ability to bind and stimulate NPR1 to produce cGMP, activating effector proteins like PRKG1, underscores its significance in vascular remodeling and energy metabolism.

Therapeutic significance:

Linked to diseases such as Atrial standstill 2 and Familial atrial fibrillation, Natriuretic peptides A's involvement in arrhythmias and cardiac rhythm disturbances highlights its potential as a target for therapeutic intervention. Understanding the role of Natriuretic peptides A could open doors to potential therapeutic strategies, especially in cardiovascular disorders.